Molecules,
Journal Year:
2023,
Volume and Issue:
28(9), P. 3849 - 3849
Published: May 1, 2023
Supercritical
carbon
dioxide
(CO2)
extraction
techniques
meet
all-new
consumer
market
demands
for
health-promoting
phytochemical
compound-rich
extracts
produced
from
green
and
sustainable
technology.
In
this
regard,
review
is
dedicated
to
discussing
the
promise
of
integrating
high-pressure
CO2
technologies
into
Cannabis
sativa
L.
processing
chain
valorize
its
valuable
pharmaceutical
properties
food
biomass.
To
do
this,
cannabis
plant,
cannabinoids,
endocannabinoid
system
were
reviewed
understand
their
therapeutic
side
effects.
The
supercritical
fluid
(SFE)
technique
was
presented
as
a
smart
alternative
producing
bioproducts.
impact
SFE
operating
conditions
on
compound
examined
aerial
parts
(inflorescences,
stems,
leaves),
seeds,
byproducts.
Furthermore,
opportunities
using
non-thermal
biomass
addressed
industrial
hemp
valorization,
focusing
biorefinery
simultaneously
produce
cannabidiol
new
ingredients
applications
plant-based
products.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(19), P. 14514 - 14514
Published: Sept. 25, 2023
Cannabidiol
(CBD),
derived
from
the
cannabis
plant,
has
gained
significant
attention
due
to
its
potential
therapeutic
benefits.
However,
one
of
challenges
associated
with
CBD
administration
is
low
bioavailability,
which
refers
fraction
an
administered
dose
that
reaches
systemic
circulation.
This
limitation
necessitates
exploration
various
approaches
enhance
bioavailability
CBD,
thus
helping
maximize
potential.
A
variety
are
now
emerging,
including
nanoemulsion-based
systems,
lipid-based
formulations,
prodrugs,
nanocarriers,
and
alternative
routes
administration,
hold
promise
for
improving
pave
way
novel
formulations
in
medical
conditions.
opinion
piece
presents
current
understanding
surrounding
considers
strategies
aimed
at
both
absorption
bioavailability.
Journal of Pharmaceutical Analysis,
Journal Year:
2023,
Volume and Issue:
13(7), P. 726 - 744
Published: April 23, 2023
Colorectal
tumors
often
create
an
immunosuppressive
microenvironment
that
prevents
them
from
responding
to
immunotherapy.
Cannabidiol
(CBD)
is
a
non-psychoactive
natural
active
ingredient
the
cannabis
plant
has
various
pharmacological
effects,
including
neuroprotective,
antiemetic,
anti-inflammatory,
and
antineoplastic
activities.
This
study
aimed
elucidate
specific
anticancer
mechanism
of
CBD
by
single-cell
RNA
sequencing
(scRNA-seq)
ATAC
(scATAC-seq)
technologies.
Here,
we
report
inhibits
colorectal
cancer
progression
modulating
suppressive
tumor
(TME).
Our
transcriptome
results
showed
suppressed
M2-like
macrophages
promoted
M1-like
in
both
strength
quantity.
Furthermore,
significantly
enhanced
interaction
between
cells
restored
intrinsic
anti-tumor
properties
macrophages,
thereby
preventing
progression.
Mechanistically,
altered
metabolic
pattern
related
signaling
pathways.
We
found
inhibited
alternative
activation
shifted
process
oxidative
phosphorylation
fatty
acid
oxidation
glycolysis
inhibiting
phosphatidylinositol
3-kinase-protein
kinase
B
pathway
downstream
target
genes.
CBD-mediated
macrophage
plasticity
response
anti-programmed
cell
death
protein-1
(PD-1)
immunotherapy
xenografted
mice.
Taken
together,
provide
new
insights
into
effects
CBD.
Journal of Clinical Sleep Medicine,
Journal Year:
2024,
Volume and Issue:
20(5), P. 753 - 763
Published: Jan. 4, 2024
Low-dose
cannabidiol
(CBD)
has
become
readily
available
in
numerous
countries;
however,
little
consensus
exists
on
its
efficacy
as
a
sleep
aid.
This
trial
explored
the
of
150
mg
CBD
(n
=
15)
compared
with
placebo
aid
primary
insomnia.
supplementation
was
hypothesized
to
decrease
insomnia
symptoms
and
improve
aspects
psychological
health,
relative
placebo.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(4), P. 2370 - 2370
Published: Feb. 17, 2024
Cannabidiol
(CBD),
a
non-psychoactive
phytocannabinoid
abundant
in
Cannabis
sativa,
has
gained
considerable
attention
for
its
anti-inflammatory,
antioxidant,
analgesic,
and
neuroprotective
properties.
It
exhibits
the
potential
to
prevent
or
slow
progression
of
various
diseases,
ranging
from
malignant
tumors
viral
infections
neurodegenerative
disorders
ischemic
diseases.
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD),
formerly
known
as
non-alcoholic
fatty
(NAFLD),
alcoholic
disease,
hepatitis
stand
prominent
causes
morbidity
mortality
chronic
diseases
globally.
The
literature
substantiated
CBD’s
therapeutic
effects
across
diverse
vivo
vitro
models.
However,
precise
mechanism
action
remains
elusive,
an
absence
evidence
hinders
translation
into
clinical
practice.
This
comprehensive
review
emphasizes
wealth
data
linking
CBD
Importantly,
we
delve
detailed
discussion
receptors
through
which
might
exert
effects,
including
cannabinoid
receptors,
CB1
CB2,
peroxisome
proliferator-activated
(PPARs),
G
protein-coupled
receptor
55
(GPR55),
transient
channels
(TRPs),
their
intricate
connections
with
In
conclusion,
address
new
questions
that
warrant
further
investigation
this
evolving
field.
Clinical and Translational Science,
Journal Year:
2025,
Volume and Issue:
18(1)
Published: Jan. 1, 2025
ABSTRACT
The
two
most
extensively
studied
cannabinoids,
cannabidiol
(CBD)
and
delta‐9‐tetrahydrocannabinol
(THC),
are
used
for
myriad
conditions.
THC
is
predominantly
eliminated
via
the
cytochromes
P450
(CYPs),
whereas
CBD
through
both
CYPs
UDP‐glucuronosyltransferases
(UGTs).
fractional
contributions
of
these
enzymes
to
cannabinoid
metabolism
have
shown
conflicting
results
among
studies.
Physiologically
based
pharmacokinetic
(PBPK)
models
drug–drug
interaction
studies
involving
or
as
object
drugs
were
developed
verified
improve
estimates
contributions.
First,
physicochemical
parameters
CBD,
THC,
their
metabolites
(7‐OH‐CBD,
11‐OH‐THC,
11‐COOH‐THC)
obtained
from
literature
optimized.
Second,
PBPK
base
after
intravenous
administration.
Third,
beginning
with
models,
absorption
oral
oromucosal
spray
administration
oral,
inhalation,
full
well‐captured
area
under
concentration–time
curve
(AUC)
peak
concentration
(
C
max
)
verification
dataset.
Predicted
AUC
7‐OH‐CBD
within
two‐fold
observed
data.
For
11‐COOH‐THC,
100%,
83%
predicted
values
two‐fold,
respectively,
values;
92%,
94%
values,
values.
could
be
help
address
critical
public
health
needs,
including
assessing
potential
drug
risks
THC.
eNeurobiología,
Journal Year:
2025,
Volume and Issue:
16(40)
Published: Jan. 6, 2025
El
cannabidiol
(CBD),
uno
de
los
principales
componentes
la
planta
Cannabis
sativa,
tiene
propiedades
farmacológicas
con
potencial
terapéutico,
por
lo
que
ha
sido
objeto
estudio
en
últimos
años.
Al
momento,
sólo
aprobado
legalmente
para
el
tratamiento
las
convulsiones
farmacorresistentes
pacientes
pediátricos.
Los
avances
realizados
investigación
acciones
terapéuticas
del
CBD
epilepsia,
se
han
sustentado
principalmente
empleo
modelos
animales.
Con
estos
animales
evaluado
un
amplio
rango
dosis,
diversas
vías
y
esquemas
administración.
A
nivel
clínico,
interacciones
farmacocinéticas/farmacodinámicas
entre
otros
fármacos
antiepilépticos,
a
fin
establecer
su
utilidad
como
coadyuvante,
realizando
ajustes
dosis
valorando
presencia
efectos
adversos
(como
inducción
enzimática
hígado).
Además,
es
una
molécula
interactúa
múltiples
blancos
moleculares
además
posee
antioxidantes
antiinflamatorias
intrínsecas.
Esta
información
nos
demostrado
anticonvulsivantes
aún
no
explorados
detalle
epilepsia
farmacorresistente,
donde
opciones
son
limitadas.
Tampoco
mecanismos
involucrados
sus
anticonvulsivos,
administración
intracerebral
podría
facilitar
esta
tarea.
desarrollo
revisión,
esperamos
lector
tenga
visión
general
estado
actual
terapéutico
solo
sino
también
farmacorresistente.
Applied Biosciences,
Journal Year:
2025,
Volume and Issue:
4(1), P. 4 - 4
Published: Jan. 21, 2025
Cannabidiol
(CBD),
a
non-psychoactive
compound
derived
from
Cannabis
sativa,
is
believed
to
have
anxiety-reducing
and
antidepressant
effects.
However,
existing
data
are
inconsistent,
likely
due
variations
in
experimental
designs,
dosages,
stress
models.
This
study
sought
assess
the
impact
of
CBD
on
anxiety
depression-like
behaviors
Wistar
rats
exposed
acute
cold
stress,
as
well
its
pro-
anti-inflammatory
cytokines.
Male
were
treated
with
(2.5,
5,
or
10
mg/kg)
vehicle
for
14
days
subjected
behavioral
tests,
including
elevated
plus
maze,
social
interaction,
forced
swim
tests.
Serum
levels
cytokines
(IL-6,
TNF-α,
IL-1β,
IL-10)
analyzed
post-experiment
using
ELISA.
Results
demonstrated
dose-dependent
anxiolytic
effect
CBD,
significant
improvements
interaction
reductions
anxiety-like
at
5
mg/kg.
All
doses
decreased
immobility
test,
suggesting
Furthermore,
selectively
lowered
IL-6
levels,
key
cytokine
depression
pathogenesis.
These
findings
indicate
that
has
properties,
partially
mediated
by
modulation
inflammatory
processes,
particularly
IL-6.
Journal of Cannabis Research,
Journal Year:
2025,
Volume and Issue:
7(1)
Published: Feb. 22, 2025
Abstract
There
is
concern
about
the
quality
of
cannabis-based
products
used
in
Brazil,
mainly
cannabidiol
(CBD).
This
study
aimed
to
evaluate
labeling
on
CBD
marketed
Brazil
authorized
by
two
regulations
–
N660/2022
imported
and
N327/2019
with
temporary
trade
permits
whether
there
were
differences
between
them
concerning
four
domains:
prescription,
good
manufacturing
practices
(GMP),
laboratory
tests,
safety
use.
Determined
was
based
a
score
45
criteria
divided
per
domain
weights
from
1
3
(according
relevance
for
users'
prescribers'
safety)
built
public
information
provided
product
manufacturers/representatives
websites
e-mail
consultations.
The
classified
as
very
satisfactory,
or
not
represented
median
interquartile
range.
Between
N327
N660
products,
scores
compared
using
Mann–Whitney
U-test.
All
tests
considered
two-tailed
hypotheses
significance
level
5%.
After
applying
inclusion
criteria,
148
selected,
105
evaluated.
Most
evaluated
satisfactory
(47),
followed
(39)
(19).
presented
that
more
accessible
than
products.
Similarly,
significant
difference
groups
domains
prescription
use;
showed
better
results
those
N660.
contributes
urgent
debate
risks
widely
Brazil.
International Journal of Molecular Sciences,
Journal Year:
2021,
Volume and Issue:
22(4), P. 1986 - 1986
Published: Feb. 17, 2021
Severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
infection
may
lead
to
disease
2019
(COVID-19)
which,
in
turn,
be
associated
with
multiple
organ
dysfunction.
In
this
review,
we
present
advantages
and
disadvantages
of
cannabidiol
(CBD),
a
non-intoxicating
phytocannabinoid
from
the
cannabis
plant,
as
potential
agent
for
treatment
COVID-19.
CBD
has
been
shown
downregulate
proteins
responsible
viral
entry
inhibit
SARS-CoV-2
replication.
Preclinical
studies
have
demonstrated
its
effectiveness
against
diseases
system
well
cardioprotective,
nephroprotective,
hepatoprotective,
neuroprotective
anti-convulsant
properties,
that
is,
effects
beneficial
Only
latter
two
properties
clinical
studies,
which
also
revealed
anxiolytic
antinociceptive
(given
alone
or
together
Δ9-tetrahydrocannabinol),
important
an
adjuvant
improve
quality
life
patients
COVID-19
limit
post-traumatic
stress
symptoms.
However,
one
should
aware
side
(which
are
rarely
serious),
drug
interactions
(also
extending
drugs
acting
COVID-19)
proper
route
administration
(vaping
dangerous).
Clearly,
further
necessary
prove
suitability
